Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Oxnard, Geoffrey R.Geoffrey R.OxnardRamalingam, Suresh S.Suresh S.RamalingamAhn, Myung-JuMyung-JuAhnKim, Sang-WeSang-WeKimYu, Helena AlexandraHelena AlexandraYuSaka, HideoHideoSakaHorn, LeoraLeoraHornGoto, KoichiKoichiGotoOhe, YuichiroYuichiroOheCantarini, MireilleMireilleCantariniFrewer, PaulPaulFrewerLahn, MichaelMichaelLahnYang, James Chih-HsinJames Chih-HsinYang2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280104[SDGs]SDG3Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.